We envision our technology “branching out” and addressing the problems of graft rejection and graft versus host disease using many approaches.

• Supressing Hybrid Antibodies - These are engineered human antibody fragments coupled with human CD8 proteins to induce veto effect and prevent transplant rejection.
• Viral Vectors - Engineered viruses that deliver the CD8 gene to induce transplant tolerance.
• Genetic Disease Therapeutics - Unique vectors developed to deliver genes repairing a genetic defect while simultaneously using veto technology to protect this gene product from rejection. Our current focus is the fight against Cystic Fibrosis.


We have recieved some questions regarding the efficacy of the use of the veto effect in therapeutics. The outcome of the valuable discussion raised by these questions can be found here.

Future Products:

• Autoimmune Disease Therapeutics- By exploiting the veto effect, our technology will be used to develop therapeutics for the treatment of autoimmune diseases.